1 | Combination Product: mavrilimumab | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [1] 41 41 💬 |
2 | MAVRILIMUMAB | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [2] 41 41, 46 💬 |
3 | Mavrilimumab 10 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [1] 46 46 💬 |
4 | Mavrilimumab 100 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [1] 46 46 💬 |
5 | Mavrilimumab 150 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [1] 46 46 💬 |
6 | Mavrilimumab 30 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [1] 46 46 💬 |
7 | Mavrilimumab 50 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬 | [1] CSF2RA CSF2RA 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [1] 46 46 💬 |